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Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by a progressive loss of dopaminergic (DA) neurons in the substantia nigra compact (SNc), depletion of dopamine in the striatum and deposition of eosinophilic inclusions (Lewy bodies) in the brain of PD patients Poewe et al., 2017; Savitt et al., 2006) . Nowadays, besides the Lewy bodies, neurites stained with antibodies to ubiquitin, α-synuclein and other biochemical markers can be detected in various brain regions, such as SN, locus cellulous, raphe, thalamus, amygdala and cerebral cortex (Braak et al., 2003; Gh Popescu and Nichol, 2011; Wong and Krainc, 2017) . These phenomena imply that PD is involved in multiple neuronal systems in addition to nigrostriatal DA neurons. Although much has been understood about pathophysiology of PD, its etiology remains not totally clear. Genes involved in processes as diverse as mitochondrial or antioxidant function and degradation pathways are impacted in the pathogenesis of PD (Beilina and Cookson, 2016; Burbulla et al., 2017; Kincses and Vecsei, 2010; Sulzer and Schmitz, 2007) . In addition, non-genetic factors, such as aging (Hindle, 2010) , pesticide exposure (Priyadarshi et al., 2001; Priyadarshi et al., 2000) , diet (Anderson et al., 1999; Galati and Di Giovanni, 2010; Johnson et al., 1999) , and inflammation have also been associated with PD. It is likely that both environmental and genetic factors contribute to DA neuron degeneration in PD.
Emerging evidence indicates that PD is not only a neurodegenerative disease, but also a systemic disorder. Peripheral inflammation and metabolic abnormality increase Journal Pre-proof 2 the incidence of PD and result in the progressive degeneration of the nigrostriatal dopaminergic system (Dunn et al., 2014; Qin et al., 2016) . Formerly, the brain was considered an immunologically privileged organ, free from immune reactions, since it is protected by the blood-brain barrier (BBB). However, accumulating investigations have demonstrated that immune responses can also occur in the brain, especially due to microglial activation (Plog and Nedergaard, 2018) . These cells are known to produce proinflammatory cytokines and their relationship with the peripheral system has been revealed. Moreover, it is known that neurovascular functions are altered in aging and neurodegenerative disorders (Iadecola, 2017; Zlokovic, 2011) , leading to abnormal states such as increased BBB permeability, decreased nutrient supply, faulty clearance of toxic molecules, and failure of enzymatic function (Popescu et al., 2009 ).
Positron emission tomography (PET) and histological studies of PD patients revealed dysfunction of the BBB transport system as well as alteration of blood vessels in the midbrain (Kortekaas et al., 2005) . Similarly, increased BBB permeability was observed in the MPTP (Chen et al., 2008) and lipopolysaccharide (LPS) models of PD (Yan et al., 2004) . Moreover, several studies on PD patients and animal models suggest a pathogenic link between BBB disruption and DA neuronal death (Cabezas et al., 2014; Liguori et al., 2017) . In addition, exploiting disrupted BBB for the delivery of nanocarriers to the diseased CNS including PD is a therapeutic approach (Pahuja et al., 2015; Umlauf and Shusta, 2019 ). These results demonstrate that BBB disruption is somehow related to neuronal cell death and neuroinflammation in PD. In addition, the leakage of the BBB might contribute to the infiltration of peripheral Journal Pre-proof 3 immune cells and peripheral harmful factors into the SN, even the drugs that cannot cross BBB under physiological conditions. In brief, penetration of peripheral immune cells or cytokines plays a critical role in the pathogenesis of PD, and systemic administration of drugs through broken BBB may has potential value for PD therapy (Machado et al., 2011) .
Dexrazoxane (ICRF-187, Dex) has been clinically used to reduce doxorubicin-induced cardiotoxicity for more than 20 years (Lipshultz et al., 2013) .
Dex, a cyclic derivative of ethylenediamine tetra-acetic acid, is a bis dioxo piperazine and is the (+)-(S)-racemate of razoxane. It has been proposed that Dex cannot penetrate the BBB for its highly hydrophilic characteristic (Hofland et al., 2005; Holm et al., 1998) . Dex may act through its rings-opened hydrolysis product ADR-925, which can either remove iron from the iron-doxorubicin complex or bind to free iron, thus preventing iron-based oxygen radical formation (Conde-Estevez and Mateu-de Antonio, 2014) . In preclinical models, dexrazoxane protected against chemotherapy-induced cardiotoxicity without affecting the antitumor activity. In mice with brain tumors, Dex reduced toxicity from high doses of etoposide and increased the treatment efficacy (Holm et al., 1998) . Hematologic toxicity, gastrointestinal toxicity and mucositis are also frequent and fatal side effects (Hainsworth and Greco, 1995) , besides cardiotoxicity from the anthracyclines. However, Dex administration limits the total dose of the anthracyclines used in chemotherapy. Dex was also used clinically as an antidote for alleviating tissue damage due to accidental anthracycline extravasation (Langer et al., 2000) . Although the cytoprotective effects of Dex are Journal Pre-proof 4 proven, it's unknown whether Dex is beneficial to PD therapy upon the destruction of BBB. In the present study, we prepared 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine plus probenecid (MPTP/p) mouse model and 6-hydroxydopamine (6-OHDA)-induced rat model of PD so as to explored the therapeutic effect of Dex on DA neuronal degeneration and to clarify the underlying mechanism. We showed that Dex could cross into broken BBB and protected DA neurons in SNc of PD animals via attenuation of oxidative damage and inhibition of systemic inflammation, including peripheral tissue and brain. Our study suggests that Dex may be a prospective drug for PD therapy.
Materials and Methods
The study protocol was approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. The National Institutes of Health guide for the care and use of Laboratory animals has been followed.
6-OHDA-induced PD model and the behavioral test
The methods of 6-OHDA model and behavioral test were described in the previous publication (Hu et al., 2010) . Briefly, male Sprague-Dawley (SD) rats (180-220 g) were anesthetized with ketamine (75 mg /kg, i.p.) and xylazine (10 mg/kg, i.p.). After anesthesia, animals were placed in a stereotaxic apparatus (Stoelting Instruments, Wood Dale, IL, USA). Unilateral injection of 6-OHDA (8 μg 6-OHDA hydrochloride in 4 μL of 0.02% ascorbic acid saline solution) was performed in the left striatum Journal Pre-proof 5 (coordinates from bregma: AP, +3.0 mm; ML, +1.0 mm; DV, -4.5 mm) with a Hamilton syringe (0.46 mm in diameter) at a rate of 0.5 μL/min, the needle was left in the place for 3 min after injection. Sham-lesioned rats were infused with 4 μL saline containing 0.02% ascorbic acid into the left striatum and served as controls. The rats after surgery were kept in cages with constant temperature (25℃) and humidity for 4 weeks. They were exposed to a 12:12-h light-dark cycle and had unrestricted access to tap water and food.
At the end of the third week after the lesion, the animals' tendency to rotate in response to apomorphine (0.5 mg/kg, s.c.) was tested. Contralateral rotations induced by apomorphine were measured with a video camera two times at weekly intervals.
Only in those animals showing at least 7 turns per min in both tests was the model considered to be successfully induced. At the end of treatment, apomorphine (0.5 mg/kg, s.c.) was administered to test for changes in the rotational behavior.
MPTP/p-induced mouse model of PD
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine plus probenecid (MPTP/p) model was described in our previous publication . Ten-week-old mice received 20 mg/kg MPTP and 250 mg/kg probenecid injection, which blocks the rapid clearance of the MPTP neurotoxin every 3.5 days for 5 weeks. (Weilbach et al., 2004) . Dex (purity >99%) was purchased from AOSAIKANG Pharmaceutical Co. Ltd (Nanjing, Jiangsu, China).
Experiment design

Rotarod test
Journal Pre-proof 7 As described in our previous publication (Lu et al., 2016) , this test is used to evaluate mice forelimb and hindlimb motor balance and coordination. The equipment was performed according to the previous publication. On the 37 th day, mice were placed in a separate compartment on the rod and tested at 20 rpm. The latency to fall was recorded.
HPLC analysis
The method was described in the previous publication (Lu et al., 2016) . Briefly, dissected striatal tissues were homogenized with 0.1M HClO 4 and 0.1mM EDTA buffer, centrifuged at 20000 rpm for 25 min. The supernatant was injected into autosampler at 4℃ (UltiMate 3000, ESA) and eluted through C18 column (2.2 μm, 120Å, 2.1×100mm, DIONEX) with catecholamine analysis mobile phase and was detected by ESA Coulochem III electrochemical detector. The mobile phase consisted 90 mM NaH 2 PO 4 , 50 mM citrate, 1.7 mM 1-octanesulfonic acid, 50 uM EDTA and 10% acetonitrile. We used external standard method of HPLC by establishing standard curve using Dex standard.
Western blotting
The method was described in previous publication . Briefly, tissue proteins were extracted using RIPA lysis and measured using BCA methods. After being uniformed, protein samples were loaded, separated using Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis and then transferred to polyvinylidene [1:800, Millipore]) at 4℃ overnight. After being washed, the membranes were incubated with the secondary antibodies (1:800, Boster) and visualized by ImageQuant™ LAS 4000 imaging system (GE Healthcare, Pittsburgh, PA, USA).
Immunostaining
Immunostaining method was described in the previous publication . SNc were counted from 4-6 samples per group. Blood-brain barrier integrity was assessed with a one-step immunoblot assay for HRP IgG in rats and mice. Perls' iron staining was carried out to observe the iron accumulation in rat SNc.
Immunofluorescence
Brain slices were rinsed with PBS, treated with 3% H2O2, permeabilized with 0.3% Triton-X100, blocked with 5% BSA and incubated with rabbit anti-p65 [1:50; CST] primary antibody at 4℃ overnight. After being washed with PBS, brain slices were incubated with Alexa Fluor 488 conjugated to anti-rabbit secondary antibody [1:1000, Invitrogen] and imaged under microscopy.
TNF-α and IL-1β assay
A sandwich enzyme-linked immunosorbent assay (ELISA) was used for detecting TNF-α and IL-1β (R&D system, Minneapolis, MN, USA) in rodent brain tissue extracts with detection limit at 5 pg/mL. The detection protocol followed the kit instructions.
Assessment of oxidative stress level
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To detect the level of lipid peroxidation in brain homogenates, malondialdehyde (MDA), a marker of oxidative stress, was measured using a commercially available thiobarbituric acid reactive substances assay kit (Cayman Chemical). The assay was performed according to the manufacturer's instructions. In brief, brain tissues were lyzed with chilled RIPA buffer and sonicated for 15 s at 40 V over ice. After centrifugation at 1600 g for 10 min at 4℃, the supernatant was collected for further analysis. The MDATBA adduct formed by the reaction of MDA in samples and TBA supplied in the assay kit under high temperature (100℃) and acidic conditions. Reaction product is measured colorimetrically at 540 nm with a spectrophotometer (Tecan M200). The content of MDA in samples was calculated using a MDA standard curve and expressed as micromolar of MDA produced per gram of protein. To detect the anti-oxidant ability of Dex in PD animal models, superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) were measured using commercially SOD assay kit (Cayman Chemical) and GSH-PX assay kit (Cayman Chemical) according to the manufacturer' s instructions. Sample preparation was the same as MDA assay' s. For SOD assay, radical detector was added followed by SOD standard or sample being added. Then xanthine oxidase was added to produce superoxide radicals and initiate reaction. After being incubated, reaction product is measured colorimetrically at 440-460 nm with a spectrophotometer (Tecan M200). For GSH-PX assay, assay buffer, co-substrate mixture, NADPH were added followed by GSH-PX standard or sample being added. Then cumene hydroperoxide was added to initiate reaction. After being incubated, reaction product is measured colorimetrically at 340 nm with a spectrophotometer (Tecan M200).
Plasma pharmacokinetics measurement
Rats of saline group or 6-OHDA group were treated with single Dex injection (15 mg/kg, i.p.). Blood was collected at 5, 10, 20, 40, 60, 90, 120, 240 
MAO-B activity assay
MAO-B activity was assayed using commercially MAO-B assay kit (GENMED) according to the manufacturer' s instructions. Samples or MAO-B standards were added into well pre-coated with MAO-B antibody. After being incubated, conjugate reagents were added followed by developing and measuring the absorbance value at 450 nm with a spectrophotometer (Tecan M200).
Statistical analysis
All data were presented as mean ± SEM. Statistical significance was assessed with one-way analysis of variance followed by a post hoc (Turkey) test for multiple group comparison. Differences with P-values of less than 0.05 were considered statistically significant.
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Dexrazoxane penetrated defect BBB of PD model animals
Emerging evidence has demonstrated that the integrity and the function of BBB are gradually impaired in the process of PD. In the present study, we thus examined the BBB integrity above all. As shown in Fig. 1, either 6-OHDA-(Fig. 1A) or MPTP-induced PD animals (Fig. 1B ) exhibited significant damage of BBB integrity, evidenced by the visible penetration of IgG in the brain tissue. We found that the plasma concentration of Dex reached peak at about 10 min after intraperitoneal injection (Fig. 1C) . Subsequently, the second peak of Dex concentration in plasma was observed at about 1 hour after intraperitoneal injection and the highest concentration of Dex was found in the brain at same time (Fig. 1D) . Furthermore, the concentration of Dex in striatum was higher than that in midbrain and cortex (Fig.   1D) . Interestingly, at the end of PD model establishing, Dex could be detected in the serum of rats in both sham+Dex15 and 6-OHDA+Dex15 groups. However, in the brain, Dex could only be detected in rats of 6-OHDA+Dex15 group whereas no detected in rats of sham+Dex15 group. Retention time of Dex in HPLC detection was 3.8-4.2 min (Fig. 1E) . Consistently, Dex could only be detected in mouse brain of MPTP/p+Dex10 group whereas no detected in mouse brain of saline+Dex10 group, although it could be detected in the serum of mice in both saline+Dex10 and MPTP +Dex10 groups (Fig. 1F&G) . These results indicated that Dexrazoxane could penetrate defect blood-brain barrier of PD model animals.
Journal Pre-proof 13
Dexrazoxane ameliorated the loss of body weight and improved the motor dysfunction of PD model
After the screening of successful 6-OHDA model, we treated 6-OHDA-lesioned rats with Dex (1.5, 5, 15 mg/kg/day, i.p.) for 3 weeks. L-DOPA (10 mg/kg/day) was used as a positive control in the present study. As shown in Fig. 2A , the average weight of vehicle-treated 6-OHDA model rats was significantly lower than that in sham group at the end of 3-week treatment. Dex administration ameliorated the weight loss of PD model mice induced by 6-OHDA. Especially, 6-OHDA+Dex (15 mg/kg) significantly increased body weight compared with that in 6-OHDA model rat. These results indicate that Dex makes better rat general state and protects rat against 6-OHDA-induced organism toxicity.
To further explore the therapeutic roles of Dex in PD, we determined whether Dex improved 6-OHDA-or MPTP-induced motor dysfunction. PD model rats had been successfully induced (> 7 turns per min contralateral rotation induced by apomorphine) at week 4 after 6-OHDA lesion, which were treated with L-DOPA or Dex for a further 3 weeks. As shown in Fig. 2B , significant protective effects that inhibited apomorphine-induced rotation were observed at the end of 2 weeks of treatment with the middle and high doses of Dex and at the end of 3 weeks of treatment with low, middle and high doses of Dex. L-DOPA treatment reduced rotation from week 1 to week 3. Next, we tested animal movement performance by a rotarod apparatus. At the end of treatment, Dex at middle and high doses significantly extended sustained rotarod time compared with that in untreated rats (Fig. 2C) .
Journal Pre-proof 14 Furthermore, mice were also evaluated 7 days after the last MPTP injection by measuring time on the rod. MPTP/p injections decreased the latency to falling to 63.7±16.2 sec, a 42.4% decrease compared with those in saline treatment group (Fig.   2D ). Dex (10 mg/kg) administration recovered MPTP-induced motor dysfunction, which also increased sustained rotarod time to 108.7±13.8 sec (Fig. 2D) . In addition, Dex (10 mg/kg) markedly reduced the foot slip number of MPTP-injured mice in 3-min observation (Fig. 2E) . These results indicate the therapeutic role of Dex in neurotoxin-induced PD-like motor dysfunction.
Dexrazoxane prevents DA neuronal degeneration in SNc and striatum of PD model animals
To examine the effects of Dex on DA neuronal degeneration, immunostaining and quantitative evaluation were used to explore the extent of tyrosine hydroxylase positive (TH + ) neuron loss in both Dex treated and untreated PD model animals. As shown in Fig. 3A&E , unilateral 6-OHDA lesion induced a dramatic loss of TH + neurons in both SNc (Fig. 3A) and striatum (Fig. 3E) of the injured hemisphere. The impairment was observed in neither region in the intact hemisphere. Dex at both 5 and 15 mg/kg doses markedly attenuated the loss of TH + immunoreactive neurons induced by 6-OHDA. High magnification (Fig. 3B ) and quantitative evaluation (Fig. 3C) confirmed that Dex at middle and high doses prevented DA neuronal degeneration in SNc of PD model rats. Furthermore, Dex (5 and 15 mg/kg) significantly reversed the ratio of injured side to intact side in TH + immunoreactive neuronal number (Fig. 3D) .
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On the other hand, Dex (10 and 30 mg/kg) administration markedly alleviated the decrease of TH + immunoreactive neuronal number in mouse SNc in response to MPTP challenge (Fig. 3F&G) . These results indicate that Dex has potential protective effects on 6-OHDA-and MPTP-induced DA neuronal degeneration in the pathogenesis of PD.
Dexrazoxane inhibits glial overactivation in the SNc of PD model animals
It has been known that activated glial cells play a critical role in DA neuron death in the process of PD. Furthermore, MPTP is converted to MPP + by monoamine oxidase-B (MAO-B) expressed predominantly in astrocytes, and then transported into DA neurons by dopamine transporter (DAT) to induce neurotoxicity. Thus, above all, we determined the degree of astrocyte and microglia activation triggered by 6-OHDA and MPTP in the SNc. As shown in Fig. 4A&B, 6 -OHDA injection evoked a dramatic increase of GFAP + cell number in SNc compared with that in sham rats, suggesting the overactivation of astrocytes. Dex administration markedly reduced the number of GFAP + cells in SNc of 6-OHDA-lesioned rats. Meanwhile, Dex (5 and 15 mg/kg) treatment for 3-week significantly decreased the number of OX42 + immunoreactive microglia in SNc of 6-OHDA-lesioned rats (Fig. 4C&D ).
Consistent with above findings, Dex at middle and high doses inhibited MPTP-induced astrocyte activation in SNc of mice. Dex alone injection had no effect on the morphology and number of astrocytes (Fig. 4E&F ). In addition, we evaluated MAO-B activity of midbrain tissues, and the result showed that Dex had no influence Journal Pre-proof 16 on MAO-B activity (Fig. 4G) . Moreover, MPTP/p injections resulted in a significant increase of Mac-1 positive cells in SNc of MPTP/p PD mice, while Dex administration dramatically suppressed the activation of microglia in SNc (Fig. 4H&I ).
These data demonstrate that Dex inhibits 6-OHDA-or MPTP-triggered glial activation, which in turn decreases the secretion of glial cell-derived harmful factors and attenuates the subsequent neuronal damage.
Dexrazoxane treatment suppresses oxidative damage in serum and brain of PD model animals
We further investigated the underlying mechanism for the effect of Dex on neurotoxin-induced DA neuronal degeneration by examining the level of MDA, a marker for lipid peroxidation in oxidative stress. As shown in Fig. 5A&D&G,   6 -OHDA stimulated massive MDA production in the serum, the lesioned midbrain and striatum compared with those in the sham group. The degree of elevation in the midbrain and striatum was significantly higher than that in the serum of PD model rats. Treatment with Dex abolished the increased MDA formation, suggesting that the protective effects of Dex on neurotoxin-induced neuronal degeneration maybe mediated by its antioxidative action. Accordingly, Dex (5, 15 mg/kg) administration markedly attenuated the reduction of GSH-PX (Fig. 5B&E&H ) and SOD activity (Fig.   5C&F&I ) in serum, midbrain and striatum of 6-OHDA-injured PD model rats.
Furthermore, Dex (10 mg/kg) significantly attenuated the alterations of MDA, GSH-PX and SOD in mouse striatum induced by MPTP (Fig. 5J&K&L) . These results confirm that Dex exerts the protective effects in periphery and brain in the pathogenesis of PD via suppressing oxidative damage.
Given that iron deposition is an important event causing oxidative damage in neurodegeneration, we thus further determined the effects of systemic Dex administration on iron deposition by Preal's iron staining. As shown in Fig. 5M&N,   6 -OHDA injection induced massive iron deposition in lesioned rat SNc, evidenced by a visible increase of Fe 3+ positive cell number. Dex (5 and 15 mg/kg) treatment for 3-week significantly eliminated the excess iron deposition and reduced Fe 3+ positive cells in the SNc of 6-OHDA-treated PD rats. This finding indicates that attenuation of iron deposition may contribute to the antioxidative role of Dex in protecting DA neurons against neurotoxin-induced degeneration.
Dexrazoxane administration attenuates systemic inflammation in PD model animals
Next, we evaluated the effect of Dex on systemic inflammation by ELISA, western blotting and immunostaining analysis. As expected, the protein levels of proinflammatory cytokines, including TNF-α and IL-1β, were markedly increased in the serum of 6-OHDA-induced PD rats compared with those in sham rats. Dex (5 and 15 mg/kg) treatment inhibited the elevation of TNF-α and IL-1β content (Fig. 6A&B) .
We also found that Dex (10 mg/kg) administration for 5 weeks significantly reduced the production of TNF-α and IL-1β in the serum of MPTP/p PD mice (Fig. 6C&D) .
Furthermore, expression of nuclear p65 in the midbrain of MPTP/p PD mice Journal Pre-proof 18 increased about 1.5-fold compared with that in saline group (Fig. 6E&F) . However, Dex (10 mg/kg) significantly reversed MPTP/p-induced the expression of nuclear p65 in mouse midbrain (Fig. 6E&F) . In addition, immunofluorescence also showed that Dex10 treated alone had no effect on nuclear p65 expression. In MPTP group, the nuclear p65 was increased and indicated by the white arrows while the less nuclear p65 expression was detected in MPTP+Dex10 group (Fig. 6G) . These results indicate that Dex attenuates systemic inflammation in both periphery and brain of PD models.
Dexrazoxane administration inhibits mesencephalon endoplasmic reticulum stress in PD model animals
It has been demonstrated that endoplasmic reticulum stress (ERS) involves DA neuron degeneration in PD and that expression of C/EBP homologous protein (CHOP), which is an ERS-induced transcription factor, can be stimulated by neurotoxin in the PD animal model. As shown in Fig. 7A , we found that treatment with Dex (15 mg/kg) for 3 weeks reversed the upregulated protein expression of GRP78 (Fig. 7B) , CHOP (Fig. 7C ) and cleaved caspase 12 (Fig. 7D) in the mesencephalon of 6-OHDA-treated PD model rats. Furthermore, Dex (10 mg/kg) administration for 5-week also significantly recovered MPTP-induced potentiation of ERS in mouse mesencephalon (Fig. 7E) , evidenced by the reduced protein levels of GRP78 (Fig. 7F) , CHOP (Fig. 7G ) and cleaved caspase 12 (Fig. 7H ). These results demonstrate that suppression of ERS is responsible for the neuroprotective effects of Dex in the pathogenesis of PD.
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Discussion
Currently, drugs available for PD therapy only provide symptomatic amelioration (Hadjiconstantinou and Neff, 2008) , while therapeutic strategies aiming at stopping or modifying disease progression are still being eagerly sought (Blandini, 2005) . Most recent studies suggest that systemic inflammation and oxidative stress in both central and peripheral system are dysregulated in PD (Lu and Hu, 2012) . Therefore, therapeutic strategies, aiming at finely modulating systemic inflammation and oxidative stress and reinstating the physiological shift toward less neurotoxic phenotypes, may represent a goal in neuroprotection. In the present study, we found that Dex, which was used to reduce doxorubicin-induced cardiotoxicity in chemotherapy, could cross into broken BBB at pathological state of PD. We further showed that Dex protected DA neurons against neurotoxin-induced degeneration and suppressed glial cell activation in SNc of PD animals. Furthermore, we demonstrate that attenuation of oxidative damage and inhibition of systemic inflammation, including peripheral tissue and brain, contribute to the neuroprotective effects of Dex in rodent model of PD. Overall, our study suggests that Dex may be a prospective drug in term of PD therapy.
Studies in experimental rodent models of PD support an involvement of peripheral proinflammatory cytokines in dopaminergic cell loss. Undoubtedly, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-OHDA induced PD models showed direct increase of cytokines including TNF-α, IL-1β and IFN-γ, which come from microglia, astrocytes, neurons or peripheral tissues (Banisadr et al., Journal Pre-proof 20 2005; Biber et al., 2006; Cartier et al., 2005; Minami et al., 2006) . Therefore, these (Bas et al., 2001; Blum-Degen et al., 1995; Dobbs et al., 1999; Hisanaga et al., 2001; Reale et al., 2009 ). Moreover, gastrointestinal infections contributing to a worsening of PD were also reported (Przuntek et al., 2004; Weller et al., 2005) , further confirming that peripheral inflammation involves the pathogenesis of PD. Actually, the influx of these peripheral cells and cytokines into the brain parenchyma could indicate a BBB dysfunction in PD patients (Hirsch and Hunot, 2009; Kortekaas et al., 2005) .
In the present study, 6-OHDA-or MPTP-induced PD animals showed significant damage of BBB integrity, evidenced by the visible penetration of IgG in the brain tissue. We found that the plasma concentration of Dex reached peak at about 10 min after intraperitoneal injection. Subsequently, the second peak of Dex concentration in plasma was observed at about 1 hour after intraperitoneal injection and the highest Journal Pre-proof 21 concentration of Dex was found in the brain at same time. Furthermore, the concentration of Dex in striatum was higher than that in midbrain and cortex. From this perspective, not only the harmful factors produced in peripheral tissues, but also the drugs that cannot cross BBB under physiological conditions may enter into brain through the injured BBB in the onset of PD.
It is well established that the brain is particularly susceptible to oxidative damage due to its high oxygen consumption and large quantities of polyunsaturated fatty acids (Lu and Hu, 2012) . 6-OHDA and MPTP, both produce endogenous reactive oxygen species and induce oxidative stress, by interfering with mitochondrial function.
Especially, MPTP is converted to MPP + by monoamine oxidase-B expressed in glial cells and then transported into DA neurons by dopamine transporter. MPP + selectively inhibits mitochondrial complex I, triggering ROS production and ER stress (Sai et al., 2013) . As a result, upregulated GRP78 and CHOP activate gene transcription, leading to glial cell activation-mediated neuroinflammation or caspase 12-mediated neuronal apoptosis (Mathur et al., 2014) . Dex significantly enhanced SOD activity and increased GSH content in both serum and midbrain of PD rats. Moreover, Dex suppressed the upregulation of GRP78, CHOP and caspase 12 in midbrain. Therefore, Dex inhibited neurotoxin-induced oxidative damage and subsequently triggered ER stress, whereby preventing DA neurons from degeneration.
Apart from oxidative stress, activation of inflammatory cells, including microglia and macrophage, with subsequent production of pro-inflammatory cytokines and molecules also aggravates PD genesis (Block and Hong, 2007) . The pro-inflammatory Journal Pre-proof 22 mediators such as TNF-a and IL-1β have been shown to synergistically contribute to neuronal damage and death in vitro and in vivo (McCoy et al., 2011) . Moreover, TNF-a level has been shown to be increased in postmortem brain and CSF from patients with PD (McCoy et al., 2011) . Therefore, macrophage and microglial activation may not just be insignificant epiphenomena of neuronal death but most likely contributes to secondary damage and further progression of neurodegeneration.
For this reason, the inhibition of macrophage and microglial activation and subsequent production of pro-inflammatory mediators may offer prospective therapeutic value for the treatment of neuroinflammation-related neurodegenerative disorders including PD. In this study, we found that Dex suppressed microglial activation in SNc and reduced the release of endogenous inflammatory mediators (TNF-a and IL-1β) in serum of PD animals. It's well known that NF-κB plays a critical role in the inflammatory pathogenesis. The anti-inflammatory effect of Dex was, therefore, further confirmed by examining its inhibitory effect on NF-κB activity.
We found in the present study that Dex suppressed the nuclear translocation of p65 subunit of NF-κB in mouse midbrain. These data confirm that Dex exerted anti-inflammatory effects via the inhibition of NF-κB pathway, in turn protected DA neurons against neurotoxin-induced degeneration.
Conclusions
The present study demonstrates for the first time that systemic administration of Dex ameliorates dopaminergic neuronal degeneration in both 6-OHDA and MPTP/p Journal Pre-proof 23 induced PD models. Dex may serve as a potential neuroprotectant to treat neurotoxin-induced neurodegeneration via attenuation of oxidative stress and ER stress, as well as the suppression of systemic inflammation in both peripheral tissues and brain. Our study indicates that Dex has potential clinical value in term of PD therapeutics.
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